- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04611880
Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
A Trial of Crizanlizumab for the Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Retinal vasculopathy with cerebral leukoencephalopathy (RVCL) is a very rare and uniformly fatal genetic condition that affects the microvasculature, especially of the brain and eye. Symptoms begin in adulthood (usually in the mid-30s to early 40s) and include loss of vision, mini-strokes, and dementia. Other patients have suffered from microvascular disease involving the kidneys, osteonecrosis, and gut ischemia. Some of these features of microvascular occlusive disease resemble ischemic events that occur during sickle cell disease. Currently, there is no effective treatment for RVCL.
The goal of this study is to test the efficacy of RVCL patients treated with crizanlizumab, a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. P-selectin is mobilized to the surface of activated vascular endothelial cells and promotes leukocyte adhesion to the blood vessel wall. The Miner laboratory has preliminarily observed a correlation with levels of soluble P-selectin and the number of brain lesions in patients with RVCL. Since leukocyte adhesion to the vascular endothelium promotes microvascular occlusion, we will determine if crizanlizumab will help to limit ischemia and brain lesions in patients with RVCL. This may lead to the development of fewer ischemic brain and eye lesions.
Up to 20 RVCL patients will receive intravenous infusions of crizanlizumab 5 mg/kg at weeks 1 and 3. Thereafter, patients will receive crizanlizumab 5 mg/kg every 28 days for a total of 24 total months. Monitoring will include standard-of-care serial MRI as well as standard-of-care eye disease monitoring at pre-defined intervals. High-risk medication monitoring will include blood work monitoring (CBC/CMP) 1 month after initiation of treatment and every 3 months thereafter. Standard-of-care assessments will be performed including radiological and physical examinations as well as eye imaging and examinations. Patients will be followed for at least 2 years after completion of crizanlizumab administration.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Andria Ford
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Perelman School of Medicine; University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A diagnosis of RVCL with confirmation by genetic test
- At least 25 years of age with imaging evidence of brain or eye disease at the time of study registration
- Normal hematologic function defined as: White blood cell count (WBC) > 4x109/L, Absolute neutrophil count (ANC) >1.5x109/L and Platelets > 100x109/L
- Females of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on study drug and for 3 months after discontinuation from study drug, and must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc), barrier method contraception (i.e. condoms), or abstinence during that time-frame
Able to understand and willing to sign an Internal Review Board (IRB)-approved written informed consent document (or that of legally authorized representative, if applicable)
-
Exclusion Criteria:
- Acute bacterial, fungal, or viral infection
- Known HIV, untreated latent tuberculosis (TB), or active hepatitis B or C infection or zoster
- Pregnant and/or breastfeeding. Negative serum pregnancy test required prior to starting study treatment. For females of child-bearing potential (FCBP), a negative urine pregnancy test is required before each infusion.
- Known hypersensitivity to one or more of the study agents
- Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug
- Liver function tests (LFTs) higher than 3x the upper limit of normal within the last 30 days
- Treatment with other monoclonal antibody medications within the last 30 days
Treatment with various forms of anticoagulation within last 30 days, including but not limited to clopidogrel or coumadin or direct thrombin inhibitors
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Single Arm Study
Single arm study: crizanlizumab will be supplied in single use vials containing 10 mL at a concentration of 10 mg/mL for administration by IV infusion.
Each patient will receive one dose of crizanlizumab on day 1 of Week 1, day 1 of Week 3, day 1 of Week 7, and then day 1 of every 4-week cycle.
On infusion day, the pharmacist or designated personnel will prepare individual doses of crizanlizumab for subjects on a milligram per kilogram basis (5 mg/kg) in a 100 mL infusion bag in accordance with the Pharmacy Manual.
Crizanlizumab will be administered over 30 minutes by IV infusion
|
Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion.
It is administered intravenously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in lesion pattern on Fluid-Attenuated Inversion Recovery (FLAIR) Magnetic Resonance Imaging (MRI) in RVCL patients.
Time Frame: year
|
Volume change in lesions of FLAIR MRI between baseline and one year is assessed.
|
year
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Kavanagh D, Spitzer D, Kothari PH, Shaikh A, Liszewski MK, Richards A, Atkinson JP. New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle. 2008 Jun 15;7(12):1718-25. doi: 10.4161/cc.7.12.6162. Epub 2008 Jun 16.
- Hasan M, Fermaintt CS, Gao N, Sakai T, Miyazaki T, Jiang S, Li QZ, Atkinson JP, Morse HC 3rd, Lehrman MA, Yan N. Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation. Immunity. 2015 Sep 15;43(3):463-74. doi: 10.1016/j.immuni.2015.07.022. Epub 2015 Aug 25.
- Wood KC, Hebbel RP, Granger DN. Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice. Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1608-14. doi: 10.1152/ajpheart.01056.2003. Epub 2004 Jan 2.
- McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997 Dec 1;100(11 Suppl):S97-103. No abstract available.
- Ford AL, Chin VW, Fellah S, Binkley MM, Bodin AM, Balasetti V, Taiwo Y, Kang P, Lin D, Jen JC, Grand MG, Bogacki M, Liszewski MK, Hourcade D, Chen Y, Hassenstab J, Lee JM, An H, Miner JJ, Atkinson JP. Lesion evolution and neurodegeneration in RVCL-S: A monogenic microvasculopathy. Neurology. 2020 Oct 6;95(14):e1918-e1931. doi: 10.1212/WNL.0000000000010659. Epub 2020 Sep 4. Erratum In: Neurology. 2021 May 11;96(19):919.
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202008079
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
-
Washington University School of MedicineCompletedVasculopathy, Retinal, With Cerebral Leukodystrophy | Cerebroretinal Vasculopathy, HereditaryUnited States
-
Novartis PharmaceuticalsCompletedAge-related Macular Degeneration | Polypoidal Choroidal VasculopathyJapan, Taiwan, Hong Kong, Singapore, Thailand, Korea, Republic of, Malaysia
-
Singapore National Eye CentreBayerCompletedAge Related Macular Degeneration | Polypoidal Choroidal VasculopathySingapore
-
Pusan National University HospitalBayerCompletedPolypoidal Choroidal Vasculopathy | Exudative Age-related Macular DegenerationKorea, Republic of
-
Salutaris Medical Devices, Inc.Not yet recruitingAge-Related Macular Degeneration | Polypoid Choroidal Vasculopathy
-
Samsung Medical CenterUnknownPolypoidal Choroidal Vasculopathy | Central Serous ChorioretinopathyKorea, Republic of
-
Oraya Therapeutics, Inc.UnknownAge Related Macular Degeneration | Polypoidal Chorodial VasculopathyItaly
-
Xun XuPeking University; Zhongshan Ophthalmic Center, Sun Yat-sen University; Air Force... and other collaboratorsUnknownAge-Related Macular Degeneration | Polypoidal Choroidal Vasculopathy | Pathological Myopia | Conbercept | PharmacogenomicChina
-
Pusan National University HospitalNovartisUnknownPolypoidal Choroidal Vasculopathy | Exudative Age-related Macular DegenerationKorea, Republic of
-
Aier School of Ophthalmology, Central South UniversityUnknownWet Macular DegenerationChina
Clinical Trials on Crizanlizumab
-
Novartis PharmaceuticalsTerminatedSickle Cell DiseaseUnited Arab Emirates, Bahrain, Kuwait, Qatar, Saudi Arabia
-
Novartis PharmaceuticalsCompleted
-
Andria FordNovartis PharmaceuticalsRecruitingSickle Cell DiseaseUnited States
-
Johns Hopkins UniversityNovartis; Brigham and Women's Hospital; Socar Research SACompleted
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsRecruitingSickle Cell DiseaseBelgium, Spain, Lebanon, United States, Brazil, France, Italy, Oman, Turkey, Germany, Colombia
-
Novartis PharmaceuticalsActive, not recruitingMyelofibrosisUnited Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
-
Novartis PharmaceuticalsRecruitingSickle Cell Disease (SCD)Germany, Spain, Belgium, Italy, Lebanon, United States, Brazil, Canada, Colombia, Oman, Switzerland, Turkey, United Kingdom, India, France
-
Novartis PharmaceuticalsAvailableSickle Cell Disease
-
Children's Hospital Los AngelesNovartisNot yet recruiting